Insights

Read our independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.

Our work is reader-supported. Sign up to our free or paid plans here.

Subcribe to Pα+
Visit the Pα+ Dashboard

The latest

Pα+ Psychedelic Bulletin #207: Lykos Rebrands to Resilient; Pharma Pushes Back on Norway’s Ketamine Reimbursement Decision; AbbVie-Gilgamesh Deal Viewed as Validation

August 28, 2025

Lykos Therapeutics Rebrands to Resilient Pharmaceuticals • Pharma Pushes Back on Norway’s Off-Label Ketamine Decision • AbbVie–Gilgamesh Deal Viewed as Validation for Short-Acting Psychedelics • Psilocybin Rescheduling Petition Heads to HHS • Sensorium Scores $25M Series A Extension to Take Kanna-Based Candidate Into Clinic • Researchers Call Lykos’ MDMA Pricing Modelling “Problematic” • Alabama Board of Medicine Issues Guidelines for Off-Label Ketamine in TRD • FDA Approves PharmaTher’s Ketamine After Two CRLs • Incannex Reports Positive Phase 2 Results for Psilocybin-Assisted Psychotherapy in GAD • and more..

AbbVie to Acquire Gilgamesh’s Bretisilocin for Up to $1.2B

August 25, 2025

AbbVie is set to buy Gilgamesh Pharmaceuticals’ lead candidate, GM-2505 (bretisilocin), in a deal worth up to $1.2bn. Here, we take a closer look at the acquisition, what it might tell us about big pharma’s interest in the field, and what it might mean for the broader crop of psychedelic drug developers…

July 2025 Psychedelic Patent Update

August 22, 2025

Explore our interactive database of psychedelic patent activity in July 2025 via our Pα+ interface. Plus, we look at how a new patent family provides a look at Rivo Bio.

Reunion Neuroscience Posts Strong Phase 2 Results for RE104 in Postpartum Depression

August 18, 2025

This morning, Reunion Neuroscience posted positive topline results from its Phase 2 study of RE104, its 4-OH-DiPT prodrug, in postpartum depression (PPD). We spoke with Reunion leadership to dig deeper into safety and efficacy data, the trial’s design and protocol, as well as the company’s plans for future development of the candidate in PPD and beyond.

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

August 15, 2025

One year after FDA’s rejection of Lykos Therapeutics’ MDMA-assisted therapy for PTSD application, insiders and observers reflect on what went wrong and what comes next. This in-depth, interview-led coverage explores the decisive factors behind the CRL, lessons learned, and the future of psychedelic drug development.

Load more

The Library

Through our years of reporting we have covered many of the topics we believe to be important to the present and future of the psychedelics space, broadly defined. However, much of this commentary is scattered across Bulletins, deep dives, special reports and year-end reviews.

The Library provides digestible explainers on salient topics across psychedelic drug development, policy and business: from basic explainers such as “what is psychedelic-assisted therapy?” through to more complex matters such as REMS programs and bifurcated scheduling.

It’s exclusively available to our Pα+ subscribers, with new content added regularly.

Subcribe to Pα+

Pα+ Library: Bifurcated Scheduling

December 6, 2023

Pα+ Library: we introduce some of the key concepts in the matter of bifurcated scheduling; a process by which an approved drug product may be placed in a different schedule to the substance itself. As we discuss in this piece, this could have significant repercussions for psychedelic research, legality, and even taxes.

Pα+ Library: Psychedelic REMS

November 15, 2023

Pα+ Library: we sketch out what a psychedelic REMS might look like, highlighting how these programs could have an outsized impact on the post-approval delivery and accessibility of these treatments.

The Psychedelic News Feed Archives

Archived versions of our Psychedelic News Feed.

Load more